Exelixis | EXEL - 股票



金融业
股票价格
USD
资产
USD 2.59B
现金及等价物
USD 226.15M
销售成本
USD 19.95M
流动资产
USD 1.21B
流动负债
USD 370.98M
债务
USD 169.54M
EBIT
USD 251.34M
EBITDA
USD 258.29M
员工
1.15K
EPS每股收益
USD 0.87
股本和储备
USD 1.94B
销售毛利
USD 590.86M
债务利息支出
USD 23.4M
利息收入
USD 16.13M
市值
USD 15.95B
净收入
USD 210.47M
营业费用
USD 359.47M
营业利润
USD 251.34M
普通股股本
USD 253.7M
PE价格收益
13.91
税前利润
USD 267.69M
销售收入
USD 610.8M
销售和管理费用
USD 139.6M
股票
USD 26.61M
贸易债权人
USD 24.15M
应收帐款人
USD 328.95M


股票 更改 日
Acadia Pharmaceuticals USD 31.57M 3.1M 2026-03
Agios Pharmaceuticals USD 35.09M 2.17M 2026-03
Akebia Therapeutics USD 13M 2.61M 2026-03
Amgen USD 6.19B 39M 2026-03
AstraZeneca USD 6.57B 13M 2026-03
Bayer EUR 12.34B 3M 2025-12
BioMarin Pharmaceutical USD 1.27B 25.66M 2026-03
Bristol-Myers Squibb USD 2.76B 66M 2026-03
Eisai JPY 236.46B 9.14B 2025-09
Eli Lilly USD 14.53B 785M 2026-03
Esperion Therapeutics USD 104.21M 915K 2026-03
Exelixis USD 26.6M 4.92M 2026-03
Genmab DKK 13M 1000K 2025-06
Glaxosmithkline GBP 6.16B 39M 2026-03
Incyte USD 115.62M 14.56M 2026-03
Ionis Pharmaceuticals USD 5.56M 4.49M 2026-03
MacroGenics USD 9.5M 1.59M 2026-03
Merck USD 6.48B 179M 2026-03
Moderna USD 146M 7M 2026-03
Nektar Therapeutics USD 14.46M 1.78M 2024-06
Neurocrine Biosciences USD 64.5M 4.5M 2026-03
Novartis USD 6.29B 17M 2026-03
Pfizer USD 10.67B 13M 2026-03
Puma Biotechnology USD 9.48M 885K 2025-09
Sanofi EUR 23.5B 812M 2026-03
Takeda JPY 1.41T 107.71B 2025-12
Ultragenyx Pharmaceutical USD 55M 3M 2026-03